摘要: Antiretroviral therapy (ART)-experienced individuals may choose to modify their regimens because of suboptimal virologic response, poor tolerability, convenience, or minimize interactions with other medications food. Constructing a new regimen for any these reasons requires thorough review prior antiretroviral drug use and available resistance results. This article summarizes the strategies used in managing ART-experienced individual who is considering modification at time response while virologically suppressed on stable regimen.
unirioja.es
elsevier.com
sci-hub.se 参考文章(80)
E Ribera, M Larrousse, A Curran, E Negredo, B Clotet, V Estrada, J Sanz, J Berenguer, R Rubio, F Pulido, P Ferrer, ML Alvarez, S Arterburn, E Martínez, Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study Hiv Medicine. ,vol. 14, pp. 327- 336 ,(2013) , 10.1111/HIV.12011
Laura Waters, , , Loveleen Bansi, David Asboe, Anton Pozniak, Erasmus Smit, Chloe Orkin, Esther Fearnhill, David Dunn, Andrew Phillips, Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antiviral Therapy. ,vol. 18, pp. 213- 219 ,(2012) , 10.3851/IMP2329
Jean-Michel Molina, Calvin Cohen, Christine Katlama, Beatriz Grinsztejn, Artur Timerman, Rog??rio de Jesus Pedro, Tony Vangeneugden, Diego Miralles, Sandra De Meyer, Wim Parys, Eric Lefebvre, Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. Journal of Acquired Immune Deficiency Syndromes. ,vol. 46, pp. 24- 31 ,(2007) , 10.1097/QAI.0B013E3181359CFB
Constance Delaugerre, Sébastien Gallien, Philippe Flandre, Dominique Mathez, Rishma Amarsy, Samuel Ferret, Julie Timsit, Jean-Michel Molina, Pierre de Truchis, Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-Patients PLoS ONE. ,vol. 7, pp. e36673- ,(2012) , 10.1371/JOURNAL.PONE.0036673
Kathleen E. Squires, Benjamin Young, Edwin DeJesus, Nicholaos Bellos, Daniel Murphy, Douglas Ward, Henry H. Zhao, Lisa L. Ross, Mark S. Shaefer, , ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine Hiv Clinical Trials. ,vol. 13, pp. 233- 244 ,(2012) , 10.1310/HCT1305-233
Josep Mallolas, Daniel Podzamczer, Ana Milinkovic, Pere Domingo, Bonaventura Clotet, Esteve Ribera, Félix Gutiérrez, Hernando Knobel, Jaime Cosin, Elena Ferrer, José Alberto Arranz, Victor Roca, Francesc Vidal, Javier Murillas, Judit Pich, Enric Pedrol, Josep M Llibre, David Dalmau, Isabel García, Miquel Aranda, Ana Cruceta, Esteban Martínez, José L Blanco, Elisa De Lazzari, José M Gatell, ATAZIP Study Group, Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study Journal of Acquired Immune Deficiency Syndromes. ,vol. 51, pp. 29- 36 ,(2009) , 10.1097/QAI.0B013E31819A226F
Ronald J Bosch, Kara Bennett, Ann C Collier, Robert Zackin, Constance A Benson, Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes. ,vol. 44, pp. 268- 277 ,(2007) , 10.1097/QAI.0B013E31802C7E20
Jose R Arribas, Andrzej Horban, Jan Gerstoft, Gerdt Fätkenheuer, Mark Nelson, Nathan Clumeck, Federico Pulido, Andrew Hill, Yvon van Delft, Thomas Stark, Christiane Moecklinghoff, The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. ,vol. 24, pp. 223- 230 ,(2010) , 10.1097/QAD.0B013E3283348944
Jade Ghosn, Giampiero Carosi, Santiago Moreno, Vadim Pokrovsky, Adriano Lazzarin, Gilles Pialoux, Jose Sanz-Moreno, Agnes Balogh, Eric Vandeloise, Sophie Biguenet, Ghislaine Leleu, Jean-Francois Delfraissy, Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen Antiviral Therapy. ,vol. 15, pp. 993- 1002 ,(2010) , 10.3851/IMP1666
David A Cooper, Roy T Steigbigel, Jose M Gatell, Jurgen K Rockstroh, Christine Katlama, Patrick Yeni, Adriano Lazzarin, Bonaventura Clotet, Princy N Kumar, Joseph E Eron, Mauro Schechter, Martin Markowitz, Mona R Loutfy, Jeffrey L Lennox, Jing Zhao, Joshua Chen, Desmond M Ryan, Rand R Rhodes, John A Killar, Lucinda R Gilde, Kim M Strohmaier, Anne R Meibohm, Michael D Miller, Daria J Hazuda, Michael L Nessly, Mark J DiNubile, Robin D Isaacs, Hedy Teppler, Bach-Yen Nguyen, None, Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. The New England Journal of Medicine. ,vol. 359, pp. 355- 365 ,(2008) , 10.1056/NEJMOA0708978